Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XTL BiopharmaceuticalsXTLB -0.35%22 EV-to-EBITDA is -9.11 as of Jul. 30, 2026. GuruFocus rates XTLB with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 410 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 243902.2% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, XTL Biopharmaceuticals's enterprise value is $6.85 Mil.
XTL Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.75 Mil. Therefore, XTL Biopharmaceuticals's EV-to-EBITDA for today is -9.11.
The historical rank and industry rank for XTL Biopharmaceuticals's EV-to-EBITDA or its related term are showing as below:
XTLB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.7 Med: 0 Max: 0
Current: -8.7
XTLB's EV-to-EBITDA is ranked worse than 100% of 410
companies
in the Biotechnology industry
Industry Median: 11.46
vs XTLB: -8.70
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
XTL Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:
XTL Biopharmaceuticals's share price for today is $2.9595.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. XTL Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XTL Biopharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's EV-to-EBITDA falls into.
XTL Biopharmaceuticals's current Enterprise Value is $6.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. XTL Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTL Biopharmaceuticals (XTLB) has a EV-to-EBITDA of -9.11 as of Jul. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on XTL Biopharmaceuticals. According to the industry distribution chart, XTL Biopharmaceuticals ranks #999999 out of 410 companies in the Biotechnology industry.
Is XTL Biopharmaceuticals' EV-to-EBITDA too high?
XTL Biopharmaceuticals' current EV-to-EBITDA is -9.11. Based on the distribution chart, XTL Biopharmaceuticals ranks #999999 out of 410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XTL Biopharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #999999 out of 410 companies for EV-to-EBITDA. This places XTL Biopharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.46, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on XTL Biopharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XTL Biopharmaceuticals's current EV-to-EBITDA is -9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current EV-to-EBITDA of -9.11. The current EV-to-EBITDA is -9.11. XTL Biopharmaceuticals' overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current EV-to-EBITDA is -9.11 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
22GF Score
Get the complete analysis for XTLB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
